The Biosimilars Quiz Game: Evaluating the Role of Biosimilars in the Management of Rheumatologic Conditions

Watch our recent quiz game on biosimilars in rheumatologic conditions.
Stanley B. Cohen, MD
Jonathan Kay, MD
Kenneth G. Saag, MD, MSc
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: November 28, 2017 Expiration: November 27, 2018

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Compare and contrast biosimilars, reference biologics, and small molecule generics with indications for rheumatologic conditions
  • Compare available safety and efficacy data for the use of biosimilars and their reference biologics in the management of rheumatologic conditions
  • Outline the potential impact of interchangeability, extrapolation of indications, and substitution on dose/response, adverse events, and clinical outcomes
  • Summarize the key steps required by the FDA to demonstrate biosimilarity between a biosimilar and its reference biologic

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Stanley B. Cohen, MD

Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director
Division of Rheumatology
Presbyterian Hospital
Co-Medical Director
Metroplex Clinical Research Center
Dallas, Texas

Stanley B. Cohen, MD, has disclosed that he has received consulting fees and funds for research support from Amgen, Boehringer Ingelheim, Coherus, Pfizer, and Sandoz.
Jonathan Kay, MD

Professor of Medicine
Timothy S. and Elaine L. Peterson Chair in Rheumatology
Division of Rheumatology
Department of Medicine
University of Massachusetts Medical School
Physician
Division of Rheumatology
Department of Medicine
UMass Memorial Medical Center
Worcester, Massachusetts

Jonathan Kay, MD, has disclosed that he has received consulting fees from Amgen, Boehringer Ingelheim, Bristol‐Myers Squibb, Janssen, Lilly, Merck, Pfizer, Roche, Samsung Bioepis, Sandoz, and UCB and funds for research support paid to his institution from AbbVie, Genentech, Lilly, Pfizer, and UCB.
Kenneth G. Saag, MD, MSc

Jane Knight Lowe Professor
Division of Clinical Immunology and Rheumatology
Vice Chair, Department of Medicine
Director
Center for Education and Research on Therapeutics
Center for Outcomes, Effectiveness Research and Education
Center of Research Translation in Gout and Hyperuricemia
University of Alabama at Birmingham
Birmingham, Alabama

Kenneth G. Saag, MD, MSc, has disclosed that he had received consulting fees from Abbott, Amgen, Ardea Biosciences/ AstraZeneca, Bayer, Bristol-Myers Squibb, Merck, and Roche/Genentech.
Stanley B. Cohen, MD

Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director
Division of Rheumatology
Presbyterian Hospital
Co-Medical Director
Metroplex Clinical Research Center
Dallas, Texas

Jonathan Kay, MD

Professor of Medicine
Timothy S. and Elaine L. Peterson Chair in Rheumatology
Division of Rheumatology
Department of Medicine
University of Massachusetts Medical School
Physician
Division of Rheumatology
Department of Medicine
UMass Memorial Medical Center
Worcester, Massachusetts

Kenneth G. Saag, MD, MSc

Jane Knight Lowe Professor
Division of Clinical Immunology and Rheumatology
Vice Chair, Department of Medicine
Director
Center for Education and Research on Therapeutics
Center for Outcomes, Effectiveness Research and Education
Center of Research Translation in Gout and Hyperuricemia
University of Alabama at Birmingham
Birmingham, Alabama

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for rheumatologists, primary care physicians, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals who are involved in the care of patients with rheumatologic conditions.

Goal

The goal of the proposed activity is to improve rheumatologists’ and other clinicians’ understanding of biosimilars and their safe and appropriate use in the care of patients with rheumatologic conditions.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 28, 2017, through November 27, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Phase I/III study of CT-P13 SC shows noninferior efficacy, similar safety vs IV in RA patients. Report from EULAR 2019 by CCO.

Released: June 21, 2019

New data from the SEMIRA study of prednisone withdrawal in patients with RA from EULAR 2019 as reported by Clinical Care Options Oncology

Released: June 19, 2019

Primary outcome analysis from the FINCH1 study of JAK-1 inhibitor filgotinib in patients with RA from EULAR 2019 as reported by Clinical Care Options.

Released: June 18, 2019

Tofacitinib monotherapy: ORAL Shift shows MTX withdrawal does not worsen RA in patients receiving tofacitinib plus MTX from EULAR 2019 reported by CCO.

Released: June 18, 2019
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Supported by independent educational grants from
Boehringer Ingelheim Pharmaceuticals, Inc.
Sandoz Inc., a Novartis Division

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?